Drugs.com - Clinical Trials

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...

Mar 18, 2025 - 07:11
 0
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...
Read More

Tags:

Previous Article

Ulta Beauty Admits Rocky Road Ahead Amid Consumer Uncertainty

Next Article

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiv...

Related Posts

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 waveLINE-010 Trial Initiation E...

Feb 9, 2025  0

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readin...

Mar 14, 2025  0

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Feb 9, 2025  0